TNFRSF1B and rheumatoid arthritis: In humans, treatment of patients with rheumatoid arthritis (RA) with the TNFR2 decoy receptor etanercept led to reduced peripheral MBCs frequencies, diminished FDC networks in tonsils, and reduced GC counts and sizes compared with methotrexate-treated patients with RA and people in the healthy control group (25).